secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001808665-24-000011
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio reports Q4 2023 net product sales $32.5M, net loss $57.4M; guides 2024 sales $110-125M, adj. EBITDA $20-30M
--------------------------------------------------------------------------------

- Q4 net product sales $32.5M (down 35% YoY); net loss $57.4M vs. income $88.6M in Q4 2022.
- Full year 2023 net product sales $149.5M (down 3.6% YoY); net loss $331.9M vs. income $109.6M.
- Non-GAAP adj. EBITDA Q4 $4.5M (down from $33.4M); adj. EPS $0.11 (vs. $0.32).
- 2024 guidance: net product sales $110-125M, adj. EBITDA $20-30M; Rolvedon sales target >$100M in coming years.
- Board appointed Sigurd Kirk, former Allergan EVP Business Development, effective April 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000180866524000011/0001808665-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000180866524000011/asrt-20240308.htm
  HTML page:      https://secwatch.observer/filing/0001808665-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer